Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1

Lantheus Holdings, Inc. (NASDAQ: LNTH) has received Transitional Pass-Through payment status from the Centers for Medicare & Medicaid Services for its PYLARIFY TruVu injection, effective October 1, 2026. This designation allows for separate reimbursement in the hospital outpatient setting, aimed at improving access to innovative diagnostic radiopharmaceuticals for Medicare beneficiaries.